ArticleCancer reports (Hoboken, N.J.)2024

Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.

Bianca Serio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.